214 related articles for article (PubMed ID: 30419845)
1. Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
Liu FR; Bai S; Feng Q; Pan XY; Song SL; Fang H; Cui J; Yang JL
BMC Cancer; 2018 Nov; 18(1):1087. PubMed ID: 30419845
[TBL] [Abstract][Full Text] [Related]
2. CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
Lin XR; Zhou XL; Feng Q; Pan XY; Song SL; Fang H; Lei J; Yang JL
J Cancer Res Clin Oncol; 2019 May; 145(5):1123-1132. PubMed ID: 30796510
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glioma by adenovirus KGHV500 encoding anti-p21Ras scFv and carried by cytokine-induced killer cells.
Qian J; Yang M; Feng Q; Pan XY; Yang LL; Yang JL
Exp Biol Med (Maywood); 2021 May; 246(10):1228-1238. PubMed ID: 33535808
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer.
Dai F; Zhang PB; Feng Q; Pan XY; Song SL; Cui J; Yang JL
J Cancer; 2021; 12(9):2768-2776. PubMed ID: 33854636
[No Abstract] [Full Text] [Related]
5. Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression.
Wang M; Hong Y; Feng Q; Pan X; Song S; Cui J; Lei J; Fang H; Yang J
Mol Ther Oncolytics; 2018 Dec; 11():90-101. PubMed ID: 30534583
[TBL] [Abstract][Full Text] [Related]
6. The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300.
Pan XY; Liu XJ; Li J; Zhen SJ; Liu DX; Feng Q; Zhao WX; Luo Y; Zhang YL; Li HW; Yang JL
Gene Ther; 2017 Jan; 24(1):40-48. PubMed ID: 27834948
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
[TBL] [Abstract][Full Text] [Related]
8. RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
Huang CC; Liu FR; Feng Q; Pan XY; Song SL; Yang JL
BMC Cancer; 2021 Mar; 21(1):321. PubMed ID: 33765976
[TBL] [Abstract][Full Text] [Related]
9. The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo.
Yang JL; Pan XY; Zhao WX; Hu QC; Ding F; Feng Q; Li GY; Luo Y
Int J Oncol; 2016 Mar; 48(3):1218-28. PubMed ID: 26780944
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
12. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).
Yoon SH; Lee JM; Woo SJ; Park MJ; Park JS; Kim HS; Park MY; Sohn HJ; Kim TG
J Clin Immunol; 2009 Nov; 29(6):806-14. PubMed ID: 19517218
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus.
Gao H; Zhang X; Ding Y; Qiu R; Hong Y; Chen W
Technol Cancer Res Treat; 2019; 18():1533033819853290. PubMed ID: 31138083
[TBL] [Abstract][Full Text] [Related]
14. RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.
Lin P; Qian J; Huang CC; Xu WM; Wang YY; Gao ZR; Zheng SQ; Wang P; Jia DQ; Feng Q; Yang JL
BMC Cancer; 2024 Jan; 24(1):71. PubMed ID: 38216883
[TBL] [Abstract][Full Text] [Related]
15. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues.
Yang JL; Liu DX; Zhen SJ; Zhou YG; Zhang DJ; Yang LY; Chen HB; Feng Q
BMC Cancer; 2016 Feb; 16():131. PubMed ID: 26897358
[TBL] [Abstract][Full Text] [Related]
16. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
17. Antitumor bioactivity of adenovirus-mediated p27mt in colorectal cancer cell line SW480.
Sun ZQ; Deng CS; Xu SY; Du Y
World J Gastroenterol; 2008 Oct; 14(38):5827-33. PubMed ID: 18855981
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models.
Zheng Y; Hu B; Xie S; Chen X; Hu Y; Chen W; Li S; Hu B
Cytotherapy; 2017 May; 19(5):617-628. PubMed ID: 28215653
[TBL] [Abstract][Full Text] [Related]
19. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
20. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
